Universidad del Desarrollo

Now showing 1 - 10 of 12

Some of the metrics are blocked by your
consent settings
Performance of the VITEK® MS system for the identification of filamentous fungi in a microbiological laboratory in Chile
(Public Library of Science (PLoS), 2024-12-23)
PORTE TORRE, LORENA ISABEL
;
Rodrigo Cruz
;
Pérez Villa, Inia
;
Carmen Varela
;
Cristina Díaz
<jats:p>Filamentous fungi are an emergent cause of severe infections in immunocompromised patients. Timely and accurate identification is crucial to initiate appropriate therapy. Traditional identification methods are time-consuming, labor-intensive, and operator-dependent. Matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometry is a rapid and easy-to-perform identification method. The effectiveness of a commercial MALDI-TOF MS platform to identify filamentous fungi in a clinical laboratory was evaluated. The study included 67 fungal isolates from 35 species/species complexes, which were identified and confirmed in mycology reference laboratories; 32 derived from clinical samples, 34 from strain collections and one was an ATCC strain. The study used the VITEK<jats:sup>®</jats:sup> MS system (v3.2.0 database), after sample extraction by VITEK<jats:sup>®</jats:sup> MS Mould Kit. Results were classified as “correct species”, “correct species complex”, “correct genus”and “no identification”. VITEK<jats:sup>®</jats:sup> MS correctly identified 91.0% of isolates (58.2% to species, 29.9% to species complex, and 1.5% to genus level only). In 82%, the result matched the species/species complex identified by reference methods. No misidentifications were observed. The kit was rapid and easy to use. In conclusion, the VITEK<jats:sup>®</jats:sup> MS system showed a high capability to accurately identify filamentous fungi in a clinical laboratory.</jats:p>
1
Some of the metrics are blocked by your
consent settings
Viral shedding and viraemia of Andes virus during acute hantavirus infection: a prospective study
(2024)
Marcela Ferrés
;
Constanza Martínez-Valdebenito
;
Carolina Henriquez
;
Claudia Marco
;
Jenniffer Angulo
10Scopus© Citations 29
Some of the metrics are blocked by your
consent settings
High-Dose Intravenous Methylprednisolone for Hantavirus Cardiopulmonary Syndrome in Chile: A Double-Blind, Randomized Controlled Clinical Trial
(2013)
Pablo A. Vial
;
Francisca Valdivieso
;
Marcela Ferres
;
Raul Riquelme
;
M. Luisa Rioseco
4Scopus© Citations 71
Some of the metrics are blocked by your
consent settings
Comparison of VSV Pseudovirus and Focus Reduction Neutralization Assays for Measurement of Anti-Andes orthohantavirus Neutralizing Antibodies in Patient Samples
(2020)
VIAL COX, MARIA CECILIA
;
Annalis Whitaker
;
Jan Wilhelm
;
Jimena Ovalle
;
Ruth Perez
4Scopus© Citations 9
Some of the metrics are blocked by your
consent settings
Correction for Khan et al., “A Multicenter Study To Evaluate Ceftaroline Breakpoints: Performance in an Area with High Prevalence of Methicillin-Resistant Staphylococcus aureus Sequence Type 5 Lineage”
(2021)
Ayesha Khan
;
Lina M. Rivas
;
Maria Spencer
;
Rodrigo Martinez
;
Marusella Lam
1 1
Some of the metrics are blocked by your
consent settings
A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus
(2015)
VIAL CLARO, PABLO AGUSTIN
;
Francisca Valdivieso
;
Mario Calvo
;
M Luisa Rioseco
;
Raul Riquelme
<jats:sec><jats:title>Background</jats:title><jats:p> In Chile, Andes virus (ANDV) is the sole aetiological agent of hantavirus cardiopulmonary syndrome (HCPS) with mean annual incidence of 55 cases, 32% case fatality rate (CFR) and no specific treatment. Neutralizing antibody (NAb) titres at hospital admission correlate inversely with HCPS severity. We designed an open trial to explore safety and efficacy and evaluate pharmacokinetics of immune plasma as a treatment strategy for this disease. </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> We performed plasmapheresis on donors at least 6 months after HCPS and measured NAb titres through a focus-reduction neutralization test. Subjects admitted to 10 study sites with suspected/confirmed HCPS were eligible for treatment with immune plasma by intravenous infusion at an ANDV NAb dose of 5,000 U/kg. HCPS was confirmed through immunoglobulin M serology or reverse transcriptase-PCR. The main outcome was mortality within 30 days. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> From 2008–2012, we enrolled and treated 32 cases and confirmed HCPS in 29. CFR of hantavirus plasma-treated cases was 4/29 (14%); CFR of non-treated cases in the same period in Chile was 63/199 (32%; P=0.049, OR=0.35, CI=0.12, 0.99); CFR of non-treated cases at the same study sites between 2005–2012 was 18/66 (27%; ( P=0.15, OR=0.43, CI=0.14, 1.34) and CFR in a previous methylprednisolone treatment study was 20/60 (33%; P=0.052, OR=0.32, CI=0.10, 1.00). We detected no serious adverse events associated to plasma infusion. Plasma NAb titres reached in recipients were variable and viral load remained stable. </jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p> Human ANDV immune plasma infusion appears safe for HCPS. We observed a decrease in CFR in treated cases with borderline significance that will require further studies for confirmation. </jats:p></jats:sec>
Scopus© Citations 56 2
Some of the metrics are blocked by your
consent settings
Hantavirus Pulmonary Syndrome, Southern Chile, 1995-2012
(2015)
Raúl Riquelme
;
María Luisa Rioseco
;
Lorena Bastidas
;
Daniela Trincado
;
Mauricio Riquelme
Scopus© Citations 32 2
Some of the metrics are blocked by your
consent settings
Molecular method for the detection of Andes hantavirus infection: validation for clinical diagnostics
(2016)
VIAL COX, MARIA CECILIA
;
Constanza Martinez-Valdebenito
;
Susana Rios
;
MARTINEZ ARENAS, JESSICA ISABEL
;
VIAL CLARO, PABLO AGUSTIN
5Scopus© Citations 28
Some of the metrics are blocked by your
consent settings
Person-to-Person Household and Nosocomial Transmission of Andes Hantavirus, Southern Chile, 2011
(2014)
Constanza Martinez-Valdebenito
;
Mario Calvo
;
VIAL COX, MARIA CECILIA
;
Rita Mansilla
;
Claudia Marco
22Scopus© Citations 90
Some of the metrics are blocked by your
consent settings
Knowledge, attitudes, and practices regarding hantavirus disease and acceptance of a vaccine trial in rural communities of southern Chile
(2017)
Francisca Valdivieso
;
GONZALEZ WIEDMAIER, CLAUDIA MARTA
;
Manuel Najera
;
Analia Cuiza
;
OLEA NORMANDIN, ANDREA MARIA
1Scopus© Citations 14

CRIS

Browse

Filters

Settings

Sort By

Results per page

Search Results